X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs PLETHICO PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA PLETHICO PHARMA ABBOTT INDIA/
PLETHICO PHARMA
 
P/E (TTM) x 35.7 -1.1 - View Chart
P/BV x 9.2 0.0 54,782.9% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 ABBOTT INDIA   PLETHICO PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
PLETHICO PHARMA
Mar-14
ABBOTT INDIA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs6,110395 1,547.2%   
Low Rs3,99631 12,766.8%   
Sales per share (Unadj.) Rs1,552.2604.4 256.8%  
Earnings per share (Unadj.) Rs188.832.5 581.3%  
Cash flow per share (Unadj.) Rs196.451.3 382.7%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.6473.6 168.2%  
Shares outstanding (eoy) m21.2534.08 62.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.30.4 923.3%   
Avg P/E ratio x26.86.6 407.9%  
P/CF ratio (eoy) x25.74.2 619.6%  
Price / Book Value ratio x6.30.5 1,409.6%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,3767,262 1,478.5%   
No. of employees `0003.3NA-   
Total wages/salary Rs m3,9371,596 246.7%   
Avg. sales/employee Rs Th9,929.3NM-  
Avg. wages/employee Rs Th1,185.1NM-  
Avg. net profit/employee Rs Th1,207.7NM-  
INCOME DATA
Net Sales Rs m32,98520,598 160.1%  
Other income Rs m1,170386 302.8%   
Total revenues Rs m34,15520,984 162.8%   
Gross profit Rs m5,2452,818 186.1%  
Depreciation Rs m162642 25.2%   
Interest Rs m381,593 2.4%   
Profit before tax Rs m6,215969 641.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,203-138 -1,591.8%   
Profit after tax Rs m4,0121,107 362.5%  
Gross profit margin %15.913.7 116.2%  
Effective tax rate %35.4-14.3 -248.1%   
Net profit margin %12.25.4 226.3%  
BALANCE SHEET DATA
Current assets Rs m22,65518,877 120.0%   
Current liabilities Rs m6,68111,896 56.2%   
Net working cap to sales %48.433.9 142.9%  
Current ratio x3.41.6 213.7%  
Inventory Days Days6536 180.3%  
Debtors Days Days29198 14.7%  
Net fixed assets Rs m8359,861 8.5%   
Share capital Rs m213341 62.4%   
"Free" reserves Rs m16,71512,331 135.6%   
Net worth Rs m16,92816,139 104.9%   
Long term debt Rs m04,706 0.0%   
Total assets Rs m24,16233,146 72.9%  
Interest coverage x163.71.6 10,180.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.40.6 219.7%   
Return on assets %16.88.1 205.8%  
Return on equity %23.76.9 345.6%  
Return on capital %36.912.3 300.6%  
Exports to sales %021.4 0.0%   
Imports to sales %015.2 0.0%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs mNA3,136 0.0%   
Fx inflow Rs m3694,402 8.4%   
Fx outflow Rs m3,8073,184 119.6%   
Net fx Rs m-3,4381,219 -282.2%   
CASH FLOW
From Operations Rs m1,5272,437 62.6%  
From Investments Rs m-2,148-6,265 34.3%  
From Financial Activity Rs m-1,0242,490 -41.1%  
Net Cashflow Rs m-1,646-1,337 123.1%  

Share Holding

Indian Promoters % 0.0 82.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 4.3 183.7%  
FIIs % 0.1 5.5 1.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 7.5 228.0%  
Shareholders   18,270 10,665 171.3%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PANACEA BIOTECH  BIOCON LTD  J.B.CHEMICALS  NATCO PHARMA  AJANTA PHARMA  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Oct 17, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS